{
  "id": 5172121,
  "title": "FDA Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes",
  "url": "https://urgent.news/2026/09/02/fda-approves-mounjaro-for-cardiovascular-risk-reduction-in-type-2",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-02T19:14:29.000Z",
  "source": {
    "name": "Healthline News",
    "slug": "healthline-news",
    "url": "https://www.healthline.com/health-news/fda-approves-mounjaro-tirzepatide-cardiovascular-risk-reduction"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration (FDA) has authorized the use of Mounjaro for reducing cardiovascular risks in individuals with type 2 diabetes who are at high risk. A large clinical trial, SURPASS-CVOT, comparing Mounjaro with Trulicity showed Mounjaro equivalent in preventing heart attacks, strokes, and cardiovascular death. Participants on Mounjaro experienced an 8% lower chance of major cardiovascular events compared to those on Trulicity. Eli Lilly, the maker of Mounjaro, announced the FDA's approval on August 28 for its use in reducing major adverse cardiovascular events (MACE) such as non-fatal heart attack, non-fatal stroke, and cardiovascular death. Kenneth Custer, from Lilly Cardiometabolic Health, highlighted that Mounjaro provides a proven method to lessen heart disease risk in those with type 2 diabetes. The approval is based on the SURPASS-CVOT, the largest and longest tirzepatide study to date, which included over 13,000 participants in 30 countries over a four-year period. The study found Mounjaro to be noninferior to Trulicity, a GLP-1 medication with proven cardiovascular benefits. Mounjaro, a dual GLP-1 and GIP receptor agonist, aids in blood sugar regulation, blood pressure reduction, weight loss, improved cholesterol levels, and reduced inflammation, all contributing to heart health. While the FDA approval is a positive development for managing type 2 diabetes and cardiovascular diseases, experts caution that the study population was very high-risk, and more research is needed to determine if Mounjaro's benefits extend to those with less severe conditions.",
  "summary": "The FDA has approved Mounjaro for cardiovascular risk reduction in people with type 2 diabetes. Milko · E+/Getty The FDA has approved Mounjaro to help reduce the risk of major cardiovascular events in people with type 2 diabetes who are at high risk. A major clinical trial found that Mounjaro performed as well as Trulicity for reducing the risk of heart attack, stroke, and cardiovascular death.…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}